NewEdge Advisors’s Travere Therapeutics TVTX Stock Holding History

NewEdge Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,461	Closed	-$247K	–	4397
2025 Q4	$247K	Buy	+6,461	New	+$210K	﹤0.01%	2454
2024 Q4	–	Sell	-13,667	Closed	-$191K	–	4026
2024 Q3	$191K	Sell	13,667 -1,586	-10%	-$16.5K	﹤0.01%	2011
2024 Q2	$125K	Buy	+15,253	New	+$103K	﹤0.01%	2056
2023 Q1	–	Sell	-13	Closed	–	–	4126
2022 Q4	$0	Buy	+13	New	+$275	﹤0.01%	4213

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NewEdge Advisors's TVTX Position: Q1 2026 in Review

NewEdge Advisors sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 6,461 shares — an estimated $247K sold.

NewEdge Advisors first reported a position in TVTX in Q4 2022 and held it in 4 quarters. The position peaked at $247K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

NewEdge Advisors reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 6,461 Travere Therapeutics shares in Q1 2026, an estimated $247K.
NewEdge Advisors first reported a position in Travere Therapeutics in Q4 2022 and held it in 4 quarters.
NewEdge Advisors's Travere Therapeutics position peaked at $247K in Q4 2025.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.